𝗟𝘂𝗺𝗶𝗻𝗮𝗿𝘆 𝗚𝗿𝗼𝘂𝗽, 𝗚𝗹𝗼𝗯𝗮𝗹 𝗟𝗶𝗳𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝗖𝗼𝗻𝘀𝘂𝗹𝘁𝗮𝗻𝗰𝘆 #artificialintelligence #realworlddata #mergersandacquisitions #realworldevidence #productlifecycle #regulatory #pharmacovigilence #bioprocessing #cdmo #clinicaltrials #consultancy #eclinical #saas #ecoa
About us
Luminary Group, headquartered at St Magnus House, 3 Lower Thames Street, Central London, EC3R 6HD, is an international executive search and business consultancy specializing in the Life Sciences and Pharmaceutical sectors. Our expertise lies within the Real World Evidence, eClinical, Artificial Intelligence, Consulting and Biotechnology disciplines with localized insights and specialized knowledge. Executive Search - Tailored executive search solutions to identify and recruit top talent for key leadership positions ranging from Chairman, Board, CEO, CCO, COO, CPO - AVP Design and Recruitment for Commercial Team Organization -Strategic planning and talent acquisition services to build high-performing commercial teams aligned with business goals. Design and Recruitment for Operations Team Organization -Expert guidance in structuring and staffing operations teams for efficient and effective business operations. Data Partnerships, Business Partnerships and M&A Consulting -Advisory assistance in forging data partnerships, leveraging our extensive network of leading RWE, RWD, and AI enterprises across the US and Europe. Additionally, we aid in cultivating business collaborations with biotechnology firms and guiding through mergers and acquisitions to foster growth and innovation. Operating globally with a presence in the USA, Europe, APAC, and the Middle East, we take pride in our exclusive talent pool, ranging from C-Suite to Managerial levels, and our exclusive partnerships with returning clients and candidates. Our collaborations extend across a diverse range of companies, from Corporate to innovative Start-Ups. For additional details, please explore our website: www.luminarygroup.co.uk
- Website
-
www.luminarygroup.co.uk
External link for Luminary Group
- Industry
- Business Consulting and Services
- Company size
- 11-50 employees
- Headquarters
- City of London
- Type
- Privately Held
- Founded
- 2023
- Specialties
- Executive Search, Headhunting, Consulting, Life Sciences, Pharmacovigilence, Regulatory Affairs, CMC, Biotechnology, Diagnostics, CRO, Clinical Trials, Cell & Gene Therapy, Machine Learning, Real World Evidence, Real World Data, eClinical, eCOA, RPO, FSP, Corporate Development, Partnerships, Data Partnerships, RWE, RWD, and Artificial Intelligence
Locations
-
Primary
City of London , GB
Employees at Luminary Group
Updates
-
𝗣𝗮𝗿𝗸𝗲𝗿 𝗜𝗻𝘀𝘁𝗶𝘁𝘂𝘁𝗲 𝗳𝗼𝗿 𝗖𝗮𝗻𝗰𝗲𝗿 𝗜𝗺𝗺𝘂𝗻𝗼𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗶𝗻𝘃𝗲𝘀𝘁𝘀 𝗮𝗻𝗼𝘁𝗵𝗲𝗿 $𝟭𝟮𝟱𝗠 𝗶𝗻𝘁𝗼 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 The Parker Institute for Cancer Immunotherapy ,a research network established by tech entrepreneur Sean Parker announced a new $125 million investment. The latest investment comes …Jedd Wolchok https://lnkd.in/dMnfYSeP
-
𝗣𝗵𝗮𝘁𝗵𝗼𝗺 𝘄𝗶𝗻𝘀 𝗹𝗮𝗯𝗲𝗹 𝗲𝘅𝗽𝗮𝗻𝘀𝗶𝗼𝗻 𝗼𝗻 𝗵𝗲𝗮𝗿𝘁𝗯𝘂𝗿𝗻 𝗱𝗿𝘂𝗴 𝘁𝗼 𝗶𝗻𝗰𝗹𝘂𝗱𝗲 𝗻𝗼𝗻-𝗲𝗿𝗼𝘀𝗶𝘃𝗲 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 Phathom Pharmaceuticals is digesting news of an expanded label for its heartburn drug Voquezna. The FDAQRC on Wednesday afternoon approved the drug for the relief … https://lnkd.in/eMH_7jfv
Phathom wins label expansion on heartburn drug to include non-erosive patients
https://endpts.com
-
𝗝&𝗝 𝗵𝗮𝘀 𝗶𝘁𝘀 𝗳𝗶𝗻𝗮𝗹 𝗼𝗳𝗳𝗲𝗿 𝗶𝗻 𝗵𝗮𝗻𝗱 𝗳𝗿𝗼𝗺 𝘁𝗵𝗲 𝗴𝗼𝘃𝗲𝗿𝗻𝗺𝗲𝗻𝘁 𝗼𝘃𝗲𝗿 𝗜𝗥𝗔 𝗽𝗿𝗶𝗰𝗶𝗻𝗴 Johnson & Johnson said the final price offers it has received under the IRA won’t affect the long-term sales growth projection it gave last year … https://lnkd.in/ew_AbcRB
J&J has its final offer in hand from the government over IRA pricing
https://endpts.com
-
𝗦𝗶𝗼𝗻𝗻𝗮 𝗹𝗶𝗰𝗲𝗻𝘀𝗲𝘀 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹-𝘀𝘁𝗮𝗴𝗲 𝗰𝘆𝘀𝘁𝗶𝗰 𝗳𝗶𝗯𝗿𝗼𝘀𝗶𝘀 𝗮𝘀𝘀𝗲𝘁𝘀 𝗳𝗿𝗼𝗺 𝗔𝗯𝗯𝗩𝗶𝗲 𝘀𝗵𝗼𝗿𝘁𝗹𝘆 𝗮𝗳𝘁𝗲𝗿 𝗹𝗮𝗿𝗴𝗲 𝗦𝗲𝗿𝗶𝗲𝘀 𝗖 Sionna Therapeutics snagged the exclusive worldwide license to three of AbbVie cystic fibrosis drug candidates as the biotech aims to beef up its work in …Michael Cloonan https://lnkd.in/deCdSr7Y
Sionna licenses clinical-stage cystic fibrosis assets from AbbVie shortly after large Series C
https://endpts.com
-
𝟰𝗗𝗠𝗧 𝗯𝘂𝗶𝗹𝗱𝘀 𝗼𝘂𝘁 𝗰𝗮𝘀𝗲 𝗳𝗼𝗿 𝘄𝗲𝘁 𝗔𝗠𝗗 𝗴𝗲𝗻𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝘄𝗶𝘁𝗵 𝗻𝗲𝘄 𝗣𝗵𝗮𝘀𝗲 𝟮 𝗱𝗮𝘁𝗮 4D Molecular Therapeutics presented new Phase 2 data for its wet AMD gene therapy, showing a durable response in a broad patient population, as it …David Kirn, MD https://lnkd.in/dvVFEznW
#ASRS24: 4DMT builds out case for wet AMD gene therapy with new Phase 2 data
https://endpts.com
-
𝗥𝗲𝗻𝗮𝗹𝘆𝘀 𝗿𝗮𝗶𝘀𝗲𝘀 $𝟯𝟳.𝟴𝗠 𝘁𝗼 𝘁𝗮𝗸𝗲 𝗧𝗿𝗮𝘃𝗲𝗿𝗲'𝘀 𝗸𝗶𝗱𝗻𝗲𝘆 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝗱𝗿𝘂𝗴 𝗶𝗻𝘁𝗼 𝗣𝗵𝗮𝘀𝗲 𝟯 𝘁𝗿𝗶𝗮𝗹 𝗶𝗻 𝗝𝗮𝗽𝗮𝗻 Japanese company biotech Renalyse Pharma has raised $37.8 million (¥6 billion) in a Series A round to work on an approval in Japan for the drug … https://lnkd.in/dKZrk2hB
Renalys raises $37.8M to take Travere’s kidney disease drug into Phase 3 trial in Japan
https://endpts.com
-
𝗦𝗶𝗼𝗻𝗻𝗮 𝗹𝗶𝗰𝗲𝗻𝘀𝗲𝘀 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹-𝘀𝘁𝗮𝗴𝗲 𝗰𝘆𝘀𝘁𝗶𝗰 𝗳𝗶𝗯𝗿𝗼𝘀𝗶𝘀 𝗮𝘀𝘀𝗲𝘁𝘀 𝗳𝗿𝗼𝗺 𝗔𝗯𝗯𝗩𝗶𝗲 𝘀𝗵𝗼𝗿𝘁𝗹𝘆 𝗮𝗳𝘁𝗲𝗿 𝗹𝗮𝗿𝗴𝗲 𝗦𝗲𝗿𝗶𝗲𝘀 𝗖 Sionna Therapeutics Therapeutics snagged the exclusive worldwide license to three of AbbVie’s cystic fibrosis drug candidates as the biotech aims to beef up its work in …Michael Cloonan https://lnkd.in/deCdSr7Y
Sionna licenses clinical-stage cystic fibrosis assets from AbbVie shortly after large Series C
https://endpts.com
-
𝗦𝗰𝗼𝗿𝗽𝗶𝗼𝗻 𝗿𝗮𝗶𝘀𝗲𝘀 $𝟭𝟱𝟬𝗠 𝘄𝗶𝘁𝗵 𝘀𝗶𝗴𝗵𝘁𝘀 𝗼𝗻 𝘁𝗵𝗲 𝗻𝗲𝘅𝘁 𝘄𝗮𝘃𝗲 𝗼𝗳 𝘁𝗮𝗿𝗴𝗲𝘁𝗲𝗱 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 Scorpion Therapeutics has a fresh $150 million to work with as it moves an experimental breast cancer drug through clinical trials in an effort to …Adam Friedman, MD, PhD https://lnkd.in/d9nD3CB8
Scorpion raises $150M for next wave of targeted cancer therapies
https://endpts.com
-
𝗔𝗹𝘇𝗵𝗲𝗶𝗺𝗲𝗿'𝘀 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 𝗔𝘀𝗰𝗲𝗻𝗲𝘂𝗿𝗼𝗻 𝗿𝗮𝗶𝘀𝗲𝘀 $𝟭𝟬𝟬𝗠 A small Swiss Biotech Association has raised a $100 million Series C to start testing its oral small molecule for Alzheimer’s disease in a Phase 2 …Barbara A. Asceneuron SA https://lnkd.in/dxmSFZ5c
Alzheimer’s biotech Asceneuron raises $100M to see if it can compete with Lilly, Biogen on tau
https://endpts.com